Drugs Made In America Acquisition Corp.DMAA
Price (close)
$10.84
Market cap
$263.2M
P/E
43.2x
Revenue (TTM)
—
Net income
$6.1M
Dividend yield
—
1-year total return
5.5%
Net margin
—
Revenue growth
—
Debt / equity
—
What Drugs Made In America Acquisition Corp. does.
are a blank check company incorporated in the Cayman Islands as an exempted company for the purpose of effecting a merger, share exchange,
asset acquisition, share purchase, recapitalization, reorganization or other similar business combination with one or more businesses.
We have neither engaged in any operations nor generated any revenue to date. Based on our business activities, the Company is a “shell
Revenue and profit, by fiscal year.
| Fiscal year | 2024 | 2025 |
|---|---|---|
| Net income | — | $5.9M |
More on DMAA.
- Drugs Made In America Acquisition Corp. summary
- Drugs Made In America Acquisition Corp. financial statements
- Drugs Made In America Acquisition Corp. key metrics
- Drugs Made In America Acquisition Corp. health scores and style box
- Drugs Made In America Acquisition Corp. earnings
- Drugs Made In America Acquisition Corp. dividends
- Drugs Made In America Acquisition Corp. valuation
- Drugs Made In America Acquisition Corp. ownership and insiders
- Drugs Made In America Acquisition Corp. peers
Figures from Drugs Made In America Acquisition Corp.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.